Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Symmetric Dimethylarginine for Risk Stratification of Cardioembolic Stroke.

Translational stroke research·2026
Same author

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same author

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same author

Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.

Archives of gynecology and obstetrics·2026
Same author

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial.

Frontiers in cardiovascular medicine·2026
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

Digitoxina en pacientes con insuficiencia cardíaca y fracción de eyección reducida

Udo Bavendiek1, Anika Großhennig2, Johannes Schwab3,4

  • 1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

The New England journal of medicine
|August 29, 2025
PubMed
Resumen

El tratamiento con digitoxina redujo significativamente el riesgo combinado de muerte o hospitalización por insuficiencia cardíaca en pacientes con fracción de eyección reducida. Este estudio establece la digitoxina como una terapia potencial para el tratamiento de la insuficiencia cardíaca.

Más Videos Relacionados

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Área de la Ciencia:

  • Cardiología
  • Farmacología
  • Ensayos clínicos

Sus antecedentes:

  • La eficacia de la digitoxina, un glucósido cardíaco, para el tratamiento de la insuficiencia cardíaca con fracción de eyección reducida (HFrEF) sigue sin probarse.
  • La terapia médica dirigida por las directrices (GDMT) es estándar para HFrEF, pero se necesitan tratamientos adicionales.

Objetivo del estudio:

  • Evaluar la eficacia terapéutica de la digitoxina en comparación con el placebo en pacientes con HFrEF que reciben GDMT.
  • Evaluar el impacto de la digitoxina en la mortalidad y las hospitalizaciones por insuficiencia cardíaca.

Principales métodos:

  • En un ensayo internacional, doble ciego y controlado con placebo, 1240 pacientes con HFrEF fueron asignados al azar para recibir digitoxina o placebo.
  • Los pacientes tenían una fracción de eyección ventricular izquierda ≤40% (clase III-IV de la NYHA) o ≤30% (clase II de la NYHA).
  • El resultado primario fue un compuesto de muerte por todas las causas o hospitalización por empeoramiento de la insuficiencia cardíaca.

Principales resultados:

  • En la población de intención de tratar modificada (1212 pacientes), la digitoxina redujo el resultado compuesto primario en un 18% (razón de riesgo, 0,82; P=0,03).
  • Durante una mediana de 36 meses, la digitoxina mostró una tendencia hacia una menor mortalidad por todas las causas (HR, 0, 86) y hospitalizaciones por insuficiencia cardíaca (HR, 0, 85).
  • Las reacciones adversas graves fueron más frecuentes en el grupo de digitoxina (4,7% frente a 2,8%).

Conclusiones:

  • El tratamiento con digitoxina redujo significativamente el riesgo combinado de muerte o hospitalización por insuficiencia cardíaca en pacientes con HFrEF tratados con GDMT.
  • La digitoxina representa una opción terapéutica potencial para el tratamiento de la insuficiencia cardíaca con fracción de eyección reducida.
  • La investigación adicional puede explorar la dosificación óptima y los perfiles de seguridad a largo plazo.